Biovica International has signed a master service agreement with a biopharmaceutical company enabling Biovica to provide its TKa testing assay and testing services. The agreement holds room for several work orders, the first of which is SEK 1.2 million. The service agreement allows Biovica to perform TKa testing services enabling evaluation of cell proliferation activities in for example pivotal drug development studies by this new customer.

The test service is focused on the use of Biovica's TKa assay and expertise within the interpretation of TKa measurement dynamics. Through the agreement, Biovica will be contributing to the development of first-in-class next generation of CDK4/6 inhibitor therapeutics in breast cancer.